<DOC>
	<DOCNO>NCT02261077</DOCNO>
	<brief_summary>Study investigate pharmacokinetics , safety tolerability Buscopan® single rise dose multiple rising dos</brief_summary>
	<brief_title>Pharmacokinetics , Safety Tolerability Rising Doses Buscopan® Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Butylscopolammonium Bromide</mesh_term>
	<mesh_term>Scopolamine Hydrobromide</mesh_term>
	<criteria>1 . Healthy male base upon complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test . There find deviate normal clinical relevance . There evidence clinically relevant concomitant disease . 2 . Age ≥21 age ≤50 year 3 . BMI ≥18.5 BMI &lt; 30 kg/m2 ( Body Mass Index ) 4 . Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation 1 . Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance 2 . Evidence clinically relevant concomitant disease 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 4 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 5 . History relevant orthostatic hypotension , faint spell blackouts 6 . Chronic relevant acute infection 7 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) judge clinically relevant investigator 8 . Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior randomization 9 . Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior enrolment study study 10 . Participation another trial investigational drug within two month prior randomization 11 . Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) 12 . Inability refrain smoke trial day judge investigator 13 . Alcohol abuse ( 40 g/day male ) 14 . Drug abuse 15 . Blood donation ( 100 mL within four week prior administration trial ) 16 . Excessive physical activity within one week prior administration trial 17 . Any laboratory value outside reference range clinical relevance 18 . Inability comply dietary regimen trial site 19 . Hypersensitivity hyoscine butylbromide and/or relate drug class 20 . History megacolon 21 . History prostatic hyperplasia 22 . History mechanical stenosis gastrointestinal ( e.g . surgery gastrointestinal tract ) 23 . History narrowangle glaucoma 24 . History tachycardic arrhythmias 25 . History myasthenia gravis 26 . Bladderneck obstruction</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>